Optibrium™, a developer of software for drug discovery, today announced the appointment of Professor Andy Black as non-executive Chair of its Board of Directors. Following the company’s recent investment from Kester Capital, the appointment will help to continue Optibrium’s strong commercial growth calling on Andy’s extensive experience in leading strategic expansion. This will include the continued advancement of software for drug discovery, focusing on the ‘hit-to-lead’ and ‘lead optimisation’ phases, extracting maximum value from pharmaceutical data, confidently targeting high-quality compounds, and accelerating discovery cycles.
Optibrium appoints Professor Andy Black as non-executive Chair
Appointment brings extensive pharmaceutical services and Board experience to drive commercial growth and development of new products to improve speed, efficiency, and productivity of drug discovery
With deep industry insight spanning more than 20 years, Andy joins Optibrium as non-executive Chair with extensive board experience, devising and leading strategic change and company growth, including chairman roles at Synetic Life Sciences, a life science industry-focused consultancy with deep expertise in the research, development and commercialisation of products, and Sygnature Discovery. As Chair of Sygnature Discovery, a leading independent provider of integrated drug discovery resource and expertise, Andy advised the company as it went through a phase of rapid growth and successful expansion in the US, adding two new sites. As Professor of Practice at King’s College London, Andy teaches on entrepreneurship and supports both the university and King’s Health Partners with commercial partnerships.
Prior to his current roles, Andy co-founded Kinapse, an international business providing expert advisory and implementation services to life science industries, sitting as CEO and subsequently Board Director. In recognition of the company’s success, Kinapse received six Fast Track Awards and was chosen by London & Partners as one of the 10 International Growth Heroes in 2016.
Dr Matthew Segall, Co-founder and CEO at Optibrium, commented: “We are delighted to be working with Andy, benefitting from his experience to guide Optibrium and continue our strong growth. His deep industry understanding, combined with having chaired private equity-backed companies through rapid expansion, makes him invaluable as a sounding board to guide our strategy and continued success.”
Professor Andy Black, Chair of the Board at Optibrium, said: “Computational drug discovery solutions are a critical component for the success of drug discovery. I am convinced by Optibrium’s products, with a rounded portfolio that includes ground-breaking AI-based next-generation solutions. I am excited to be working with this driven and exceptional team and continue to help our customers transform drug discovery.”
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.